Q-omics provides the consensus-scored UBTFL8 profile across patient tissues and cancer cell-line models. UBTFL8 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, UBTFL8 is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, UBTFL8 RNA expression shows 6,787 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, HNSC, and STAD as cancer lineages where UBTFL8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBTFL8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBTFL8 survival associations across molecular data types. UBTFL8 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBTFL8 RNA expression–survival associations across cancer types. High UBTFL8 expression shows unfavorable associations in KICH, PAAD, KIRC and ACC, but favorable associations in LUAD and LUSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for UBTFL8 RNA expression.
This table summarizes UBTFL8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for UBTFL8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBTFL8 shows lower tumor expression in KICH and higher tumor expression in HNSC and LUAD. The HNSC box plot shows higher UBTFL8 RNA expression in tumor versus normal tissue (log2 FC = +0.053, t-test p < 0.001).
This table shows molecular features associated with UBTFL8 in patient tissues and cancer cell lines. In patient samples, UBTFL8 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
